Sleep apnea should be excluded from state medical cannabis programs, according to a position statement from the American Academy of Sleep Medicine (AASM).
In November 2017 the Minnesota Department of Health announced the decision to add obstructive sleep apnea as a new qualifying condition for the state's medical cannabis program.
"Until we have further evidence on the efficacy of medical cannabis for the treatment of sleep apnea, and until its safety profile is established, patients should discuss proven treatment options with a licensed medical provider at an accredited sleep facility," said lead author Dr. Kannan Ramar, professor of medicine in the division of pulmonary and critical care medicine at Mayo Clinic in Rochester, Minnesota.
The position statement is published in the April 15 issue of the Journal of Clinical Sleep Medicine.
Obstructive Sleep Apnea
Obstructive sleep apnea should be suspected in overweight middle aged adults who snore loudly and which can cause interruption of breathing for 10 seconds or more and this results in reduced blood o
Advertisement
‘Sleep apnea should be excluded from the list of chronic medical conditions for state medical cannabis programs due to unreliable delivery methods and insufficient evidence of treatment effectiveness, tolerability and safety - American Academy of Sleep Medicine (AASM).’
Tweet it Now
Nearly 30 million adults in the U.S. have obstructive sleep apnea, a chronic disease that involves the repeated collapse of the upper airway during sleep. Common warning signs include snoring and excessive daytime sleepiness. After early animal studies demonstrated that the synthetic cannabis extract dronabinol improved respiratory stability, recent studies in humans have explored the potential use of dronabinol as an alternative treatment for sleep apnea. However, dronabinol has not been approved by the U.S. Food and Drug Administration for the treatment of sleep apnea, and its long-term tolerability and safety are still unknown. Furthermore, there have been no studies of the safety and efficacy of other delivery methods such as vaping or liquid formulation. Treatment with the use of medical cannabis also has shown adverse effects such as daytime sleepiness, which may lead to unintended consequences such as motor vehicle accidents.
"Until there is sufficient scientific evidence of safety and efficacy, neither marijuana nor synthetic medical cannabis should be used for the treatment of sleep apnea," said AASM President Dr. Ilene Rosen. "Effective and safe treatments for sleep apnea are available from licensed medical providers at accredited sleep facilities."
There are more than 2,500 AASM-accredited sleep facilities across the U.S. Treatment options for sleep apnea include CPAP therapy, which uses mild levels of air pressure, provided through a mask, to keep the throat open while you sleep.
Source: Eurekalert
Source: Eurekalert
Marijuana
Marijuana (cannabis) is a drug obtained from the hemp plant and often abused for its psychoactive effects, though it has medicinal uses as well.
Advertisement
 Quiz on Obstructive Sleep ApneaDo you feel sleepy all day despite sleeping normal hours? One of the possible reasons for this sleepiness could be obstructive sleep apnea. Test your knowledge on obstructive sleep apnea by taking this quiz. | Advertisement
|
Foods Inducing Sound Sleep
Insomnia has become a serious health problem and people tend to depend on quick yet risky solutions to get rid of it. But here is the list of nature's best sleep inducing foods right in our kitchen.
Advertisement
Recommended Readings
Latest Research News
South Korea's total fertility rate, averaging the number of children a woman aged 15-49 has in her lifetime, dropped to 0.81.
Scientists identified mechanisms governing immune cells, selectively removing troublemakers to reshape skin immunity. Benefits those with psoriasis, vitiligo.
By 2050, an anticipated increase from 494 million cases in 2020 to 1.06 billion people with musculoskeletal disabilities is expected.
Experts consulted by GlobalData anticipate a significant overhaul in the Gaucher disease scenario because of forthcoming gene therapies in development.
Within the seven major markets, 12% to 20% of diagnosed prevalent NASH cases present severe liver damage (stage 4 liver fibrosis), denoting cirrhosis.